Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959035 · ClinicalTrials.gov registry record · Phase 3
Aripiprazole Once-monthly in Patients With Schizophrenia
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 88
- Enrollment target
NCT01959035 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 88 participants.
The verdict
NCT01959035, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 88 participants
- Enrollment target
Study Summary
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.
Interventions
- DRUG Aripiprazole once-monthly
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959035
The ClinicalTrials.gov registry entry for NCT01959035 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aripiprazole once-monthly is the first listed.
NCT01959035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959035 about?
NCT01959035 is a clinical study titled "Aripiprazole Once-monthly in Patients With Schizophrenia". To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.
What is the current status of trial NCT01959035?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2013-10. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01959035?
The interventions under investigation include: Aripiprazole once-monthly (DRUG).
Who is sponsoring clinical trial NCT01959035?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.